Status:
UNKNOWN
Russian Prospective Multicenter Registry Study of Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
Lead Sponsor:
Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health
Conditions:
The Aim the Study is to Collect and Analyze Data on Patients With Acute Ischemic Stroke During Intravenous Thrombolytic Therapy With Alteplase
Eligibility:
All Genders
18-80 years
Brief Summary
Russian prospective multicenter registry study of intravenous thrombolytic therapy for acute ischemic stroke.
Detailed Description
1. RATIONALE FOR THE STUDY 1.1. The urgency of the problem Cerebral stroke ranks second in the frequency of deaths from diseases of the circulatory system in the Russian Federation. Mortality rates fr...
Eligibility Criteria
Inclusion
- To be included in the study, patients must meet the following criteria:
- Patients of any sex and age with a confirmed diagnosis of ischemic stroke (AII);
- Carrying out the patient with intravenous thrombolytic therapy with the drug alteplase (Revelisa®).
- \-
Exclusion
- \-
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04674293
Start Date
January 1 2020
End Date
January 1 2022
Last Update
December 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal State Budgetary Institution "Federal Center for Brain and Neurotechnologies" of the Federal Medical and Biological Agency
Moscow, Ostrovityanova Street, 1, P. 10, Russia, 117997